This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Samuel G. Siris, MD; Daniel P. van Kammen, MD, PhD; John P. Docherty, MD

Arch Gen Psychiatry. 1978;35(11):1368-1377.

Abstract
• This review surveys the therapeutic efficacy of tricyclic antidepressants and monoamine oxidase inhibitors in schizophrenic patients. In general, the use of these drugs alone was found not to be warranted in schizophrenia, except perhaps in the so-called pseudoneurotic subgroup. In most cases, combinations of antidepressants and phenothiazines were not more beneficial than phenothiazines alone. In particular, the conditions of agitated patients and patients with histories of social deviance dating back to childhood were often made worse by the addition of an antidepressant. However, when the patients who demonstrated symptoms of clinical depression other than anergia were isolated from several of these studies, it was found that they constituted a subgroup that was often benefited by use of these combinations. Favorable and unfavorable clinical response patterns are discussed, and recommendations for future research are outlined.

Author Affiliations
From the Section on Neuropsychopharmacology, Adult Psychiatry Branch, National Institute of Mental Health, Bethesda, Md. Dr Siris is presently with the Affective Disorders Research Service, New York State Psychiatric Institute, New York. Dr Docherty is presently with the Department of Psychiatry, Yale University, New Haven, Conn.

Footnotes
Accepted for publication Nov 1, 1977.

Read in part before the 129th annual meeting of the American Psychiatric Association, Miami, May 14, 1976.

Reprint requests to Affective Disorders Research Service, New York State Psychiatric Institute, 722 W 168th St, New York, NY 10032 (Dr Siris).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Role of Selegiline in the Treatment of Negative Symptoms Associated with Schizophrenia
Fohey et al.
The Annals of Pharmacotherapy 2007;41:851-856.
ABSTRACT | FULL TEXT  

Double-Blind, Placebo-Controlled, Multicenter Trial of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Outpatients With Schizophrenia
Bodkin et al.
Am. J. Psychiatry 2005;162:388-390.
ABSTRACT | FULL TEXT  

A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia
Mulholland et al.
J Psychopharmacol 2003;17:107-112.
ABSTRACT  

Schizophrenia
Kane
NEJM 1996;334:34-42.
FULL TEXT  

Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients
Hogarty et al.
Arch Gen Psychiatry 1995;52:29-41.
ABSTRACT  

Maintenance Imipramine Therapy for Secondary Depression in Schizophrenia: A Controlled Trial
Siris et al.
Arch Gen Psychiatry 1994;51:109-115.
ABSTRACT  

Antidepressants in 'Depressed' Schizophrenic Inpatients: A Controlled Trial
Kramer et al.
Arch Gen Psychiatry 1989;46:922-928.
ABSTRACT  

Adjunctive Imipramine in the Treatment of Postpsychotic Depression: A Controlled Trial
Siris et al.
Arch Gen Psychiatry 1987;44:533-539.
ABSTRACT  

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics
Mandel et al.
Arch Gen Psychiatry 1982;39:197-203.
ABSTRACT  

Postpsychotic Depressive Symptoms in Hospitalized Schizophrenic Patients
Siris et al.
Arch Gen Psychiatry 1981;38:1122-1123.
ABSTRACT